Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Read now
Jessica Craddock & Silva Markovic-Plese. (2015) Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Expert Review of Clinical Pharmacology 8:3, pages 283-296.
Read now
Read now
Articles from other publishers (7)
Aigli G Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, Evangelos Koumasopoulos, Panos Stathopoulos, Maria-Eleftheria Evangelopoulos, Leonidas Stefanis, Christine Stadelmann-Nessler & Constantinos Kilidireas. (2023) Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice. International Immunopharmacology 125, pages 111192.
Crossref
Crossref
Kyle W. Anderson, Christina Bergonzo, Kerry Scott, Ioannis L. Karageorgos, Elyssia S. Gallagher, Venkata S. Tayi, Michael Butler & Jeffrey W. Hudgens. (2022) HDX-MS and MD Simulations Provide Evidence for Stabilization of the IgG1—FcγRIa (CD64a) Immune Complex Through Intermolecular Glycoprotein Bonds. Journal of Molecular Biology 434:2, pages 167391.
Crossref
Crossref
Aigli G. Vakrakou, Dimitrios Tzanetakos, Maria-Eleptheria Evangelopoulos, George E. Fragoulis, Paraskevi Kazakou, Eleni Lekka, Nikolitsa Kafasi, John S. Tzartos, Elissavet Andreadou, Georgios Koutsis, Elias Gialafos, Antonios Dimitrakopoulos, Evanthia Zampeli, Dimitra Rontogianni, Stamatios Theocharis, Evangelia Zapanti, Panos-Alexis Stathopoulos, Maria Anagnostouli, Leonidas Stefanis & Constantinos Kilidireas. (2021) IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients. Journal of Neuroimmunology 361, pages 577759.
Crossref
Crossref
Kyle W. Anderson, Kerry Scott, Ioannis L. Karageorgos, Elyssia S. Gallagher, Tayi Venkata S., Michael Butler & Jeffrey W. Hudgens. (2021) Dataset from HDX-MS Studies of IgG1 Glycoforms and Their Interactions
with the FcγRIa (CD64) Receptor. Journal of Research of the National Institute of Standards and Technology 126.
Crossref
Crossref
A. García Merino, J.R. Ara Callizo, O. Fernández Fernández, L. Landete Pascual, E. Moral Torres & A. Rodríguez-Antigüedad Zarrantz. (2017) Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurología (English Edition) 32:2, pages 113-119.
Crossref
Crossref
A. García Merino, J.R. Ara Callizo, O. Fernández Fernández, L. Landete Pascual, E. Moral Torres & A. Rodríguez-Antigüedad Zarrantz. (2017) Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología. Neurología 32:2, pages 113-119.
Crossref
Crossref
Jan Dörr & Friedemann Paul. (2015) The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology 17:6.
Crossref
Crossref